Amgen announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.

The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate innovative advanced technologies throughout the operations process. It is expected to create nearly 750 jobs, including construction roles and new highly skilled manufacturing jobs. 

"This expansion underscores Amgen's commitment to U.S. biomanufacturing and to strengthening the resilience of our global supply chain," said Robert A. Bradway, chairman and chief executive officer at Amgen. "By growing our capacity to deliver innovative medicines with cutting edge technology in our manufacturing plants, we will not only better serve patients but also create high-quality jobs that reinforce America's leadership in biotechnology."

"Amgen's multimillion-dollar expansion reflects a bond of mutual loyalty: Amgen's sustained investment and Puerto Rico's skilled, resilient workforce reinforcing each other over time," said Puerto Rico Governor Jenniffer González Colón. "This new expansion not only strengthens U.S. supply chain security through reshoring, it also opens new horizons for our people as we build an innovation ecosystem that positions Puerto Rico as the strongest biopharmaceutical hub in the United States."

"Puerto Rico boasts more than 60 years of expertise and excellence in the biopharmaceutical sector, supported by highly skilled talent and world-class infrastructure," said Sebastián Negrón Reichard, Puerto Rico Secretary of the Department of Economic Development and Commerce. "This investment by Amgen is a testament to how committed we are to advancing a competitive and innovative ecosystem that allows global companies to grow and prosper in Puerto Rico."

Amgen's long-standing commitment to U.S. innovation and state-of-the-art operations is reflected in more than $40 billion invested in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017. The enactment of pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, further facilitates Amgen's ability to invest domestically in cutting-edge science and manufacturing.

This announcement builds on Amgen's recent investments, including a $600 million science and innovation center in California and manufacturing expansions of $900 million in Ohio and $1 billion in North Carolina, respectively.